Albireo Pharma (NASDAQ:ALBO) Rating Reiterated by HC Wainwright

Share on StockTwits

HC Wainwright reiterated their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report published on Wednesday morning, AnalystRatings.com reports. HC Wainwright currently has a $62.00 target price on the biopharmaceutical company’s stock.

ALBO has been the topic of several other research reports. William Blair restated an outperform rating on shares of Albireo Pharma in a research note on Thursday, May 9th. Zacks Investment Research lowered Hess Midstream Partners from a hold rating to a sell rating in a research note on Tuesday, May 14th. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. BidaskClub upgraded Viacom from a sell rating to a hold rating in a research note on Friday, July 5th. Finally, Cowen restated a market perform rating and set a $99.00 price target (up previously from $97.00) on shares of United Continental in a research note on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and an average target price of $54.25.

Shares of Albireo Pharma stock opened at $28.43 on Wednesday. Albireo Pharma has a 12 month low of $19.10 and a 12 month high of $38.69. The company’s fifty day moving average price is $32.15.

Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.20 million. Albireo Pharma had a negative net margin of 2,900.81% and a negative return on equity of 47.03%. As a group, analysts forecast that Albireo Pharma will post -5.99 EPS for the current year.

Several institutional investors have recently made changes to their positions in ALBO. Metropolitan Life Insurance Co. NY grew its stake in Albireo Pharma by 356.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 3,328 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,599 shares during the last quarter. Bank of America Corp DE grew its stake in Albireo Pharma by 87.6% in the fourth quarter. Bank of America Corp DE now owns 6,469 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 3,020 shares during the last quarter. Rhumbline Advisers grew its stake in Albireo Pharma by 40.2% in the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock valued at $320,000 after purchasing an additional 3,743 shares during the last quarter. Hartwell J M Limited Partnership grew its stake in Albireo Pharma by 17.8% in the first quarter. Hartwell J M Limited Partnership now owns 14,250 shares of the biopharmaceutical company’s stock valued at $459,000 after purchasing an additional 2,150 shares during the last quarter. Finally, Private Advisors LLC grew its stake in Albireo Pharma by 3.4% in the first quarter. Private Advisors LLC now owns 15,198 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 70.41% of the company’s stock.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: What is a CD ladder?

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.